I think the price it can achieve with a $18 to $20 million revenue is depends on what else we learn in the call. If we hear everything is going fine with generic Oxy and Vyvanse or some other unexpected event we should leap back up into the hot OTC territory. But regardless of what the short-term view you are focusing on is, this company is going to be sold in a couple of years for much more than shares are being sold at now. I am not going to hazard a guess other than to say I think it will be at least 5 times more than what it is now. To make crazy profits an investor has to be crazy patient.
News 
Market Data 
Discover 
AI
